Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas’ disease drug discovery

Lorna MacLean (Lead / Corresponding author), John Thomas, Michael D. Lewis, Ignacio Cotillo, David Gray (Lead / Corresponding author), Manu De Rycker

Research output: Contribution to journalArticlepeer-review

70 Citations (Scopus)
211 Downloads (Pure)


Chagas’ disease is responsible for significant mortality and morbidity in Latin America. Current treatments display variable efficacy and have adverse side effects, hence more effective, better tolerated drugs are needed. However, recent efforts have proved unsuccessful with failure of the ergosterol biosynthesis inhibitor posaconazole in phase II clinical trials despite promising in vitro and in vivo studies. The lack of translation between laboratory experiments and clinical outcome is a major issue for further drug discovery efforts. Our goal was to identify cell-based assays that could differentiate current nitro-aromatic drugs nifurtimox and benznidazole from posaconazole. Using a panel of T. cruzi strains including the six major lineages (TcI-VI), we found that strain PAH179 (TcV) was markedly less susceptible to posaconazole in vitro. Determination of parasite doubling and cycling times as well as EdU labelling experiments all indicate that this lack of sensitivity is due to the slow doubling and cycling time of strain PAH179. This is in accordance with ergosterol biosynthesis inhibition by posaconazole leading to critically low ergosterol levels only after multiple rounds of division, and is further supported by the lack of effect of posaconazole on the non-replicative trypomastigote form. A washout experiment with prolonged posaconazole treatment showed that, even for more rapidly replicating strains, this compound cannot clear all parasites, indicative of a heterogeneous parasite population in vitro and potentially the presence of quiescent parasites. Benznidazole in contrast was able to kill all parasites. The work presented here shows clear differentiation between the nitro-aromatic drugs and posaconazole in several assays, and suggests that in vitro there may be clinically relevant heterogeneity in the parasite population that can be revealed in long-term washout experiments. Based on these findings we have adjusted our in vitro screening cascade so that only the most promising compounds are progressed to in vivo experiments.
Original languageEnglish
Article numbere0006612
Pages (from-to)1-22
Number of pages22
JournalPLoS Neglected Tropical Diseases
Issue number7
Publication statusPublished - 12 Jul 2018


  • Biological Assay/methods
  • Chagas Disease/drug therapy
  • Drug Discovery/methods
  • Ergosterol/biosynthesis
  • Humans
  • Triazoles/pharmacology
  • Trypanocidal Agents/pharmacology
  • Trypanosoma cruzi/drug effects


Dive into the research topics of 'Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas’ disease drug discovery'. Together they form a unique fingerprint.

Cite this